Novagali Pharma

Novagali Pharma Announces the Registration of its "document de base" With the French Securities Market Authority ("Autorité des marchés financiers" - AMF)

    Evry, France (ots/PRNewswire) - In preparation for the application for the listing of its shares on Eurolist by Euronext, Novagali Pharma, an emerging ophthalmic pharmaceutical company, announces that its document de base was registered on July 18, 2007 by the Autorité des marchés financiers (AMF) under number I.07-132.

    The document de base is available free of charge from Novagali Pharma, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, 91000 Evry, France, on the AMF website ( and on the Novagali Pharma website (

    The public attention is drawn to the chapter 4 of the document de base, entitled 'Risk Factors'.

    This communication is not intended to be used, and cannot be used, by the recipient or any other person for the purpose of avoiding United States federal tax penalties that may be imposed on the recipient or such other person. In addition, if any United States federal tax advice contained in this communication is used or referred to in promoting, marketing or recommending any corporation, partnership or other entity, investment plan, concept, structure or arrangement (which should be assumed to be the case by a recipient or other person who is not our client with respect to the subject matter of the communication), then (i) such tax advice should be construed as written to support the promotion or marketing of the transactions or matters addressed by the advice and (ii) the recipient or other person should seek advice based on the recipient or other person's particular circumstances from an independent tax advisor. For further information, please go to

    About Novagali Pharma :

    Novagali Pharma is an emerging ophthalmic pharmaceutical company based in the Génopôle biocluster in Evry (France), that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 8 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cationorm(R), a CE mark product for dry eye relief, and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, Novagali Pharma has raised a total amount of Euro 44 million in 3 series of financing.

ots Originaltext: Novagali Pharma
Im Internet recherchierbar:

Press contacts: Novagali Pharma, Geneviève Garrigos,
+33-1-69-87-40-20 / +33-6-65-54-60-19,; Euro RSCG, Estelle Griffe,
+33-1-58-47-95-25 / +33-6-23-75-09-23,

Weitere Meldungen: Novagali Pharma

Das könnte Sie auch interessieren: